Diagnostic value evaluation of trefoil factors family 3 for the early detection of colorectal cancer

Table 1 Clinical characteristic of the individuals in our study n (%)

Clinical characteristics	Colorectal cancer group		Colorectal adenoma group		Healthy control group
	Training(n = 214)	Validation(n = 132)	Training(n = 198)	Validation(n = 104)	Training(n = 115)	Validation(n = 107)
Age, yr
Median	58	60	57	56	55	53
Range	43-72	41-76	41-70	36-73	38-68	39-62
Sex
Male	128 (59.81)	84 (63.64)	107 (54.04)	62 (59.62)	61 (53.04)	56 (52.34)
Female	86 (40.19)	48 (36.36)	91 (45.96)	42 (40.38)	54 (46.96)	51 (47.66)
Location
Colon	102 (47.66)	64 (48.48)	104 (52.53)	56 (53.85)	-	-
Rectum	112 (52.34)	68 (51.52)	94 (47.47)	48 (46.15)	-	-
Differentiation grade
Well + moderately	126 (58.88)	68 (51.52)	-	-	-	-
Poorly	88 (41.12)	64 (48.48)	-	-	-	-
Stage
A + B	82 (38.32)	56 (42.42)	-	-	-	-
C + D	132 (61.68)	76 (57.58)	-	-	-	-

CRC: Colorectal cancer; CA: Colorectal adenoma; HC: Healthy control; CEA: Carcino-embryonic antigen.

Table 2 Diagnostic evaluation of trefoil factors family, carcino-embryonic antigen alone or combination for discriminating colorectal adenoma and colorectal cancer in the training group

Indicator	Groups	AUC (95%CI)	Cutoff value	Sensitivity	Specificity
TFF3	CA vs CRC	0.834 (0.796, 0.873)	29.89	75.23%	78.28%
	CA vs early stage CRC	0.751 (0.691, 0.812)	29.89	58.54%	78.28%
	CA vs advanced CRC	0.886 (0.849, 0.923)	34.07	75.00%	89.39%
CEA	CA vs CRC	0.683 (0.630, 0.737)	4.96	57.01%	85.86%
	CA vs early CRC	0.648 (0.563, 0.734)	4.53	56.10%	81.31%
	CA vs advanced stage CRC	0.705 (0.641, 0.770)	4.96	60.61%	85.86%
TFF3+CEA	CA vs CRC	0.883 (0.851, 0.915)	0.57	73.83%	88.38%
	CA vs early stage CRC	0.823 (0.768, 0.878)	0.41	76.83%	77.27%
	CA vs advanced stage CRC	0.919 (0.888, 0.951)	0.57	81.82%	88.38%

TFF3: Trefoil factors family; CA: Colorectal adenoma; CRC: Colorectal cancer; AUC: Area under curve.